Latest News for: igm

Edit

Statement of Changes in Beneficial Ownership (Form 4) (IGM Biosciences Inc)

Public Technologies 18 Mar 2025
) FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) ... IGM Biosciences, Inc. [IGMS] 5 ... C/O IGM BIOSCIENCES, INC., 325 E MIDDLEFIELD ROAD 3 ... C/O IGM BIOSCIENCES, INC ... IGM Biosciences Inc.
Edit

Analyst presentation (2024 q2 igm analyst presentation final v1.1) (IGM Financial Inc)

Public Technologies 18 Mar 2025
Certain statements in this report, other than statements of historical fact, are forward-looking statements based on certain assumptions and reflect IGM Financial Inc.'s (IGM Financial, IGM or the ...
Edit

Amendment to Current Report (Form 8-K/A) (IGM Biosciences Inc)

Public Technologies 06 Mar 2025
... IGM-2644, an IGM-based CD38 X CD3 bispecific antibody T cell engager, for autoimmune diseases, including an approximately 73% reduction in force to preserve cash (the "2025 Restructuring").
Edit

Initial Registration Statement for Employee Benefit Plan (Form S-8) (IGM Biosciences Inc)

Public Technologies 06 Mar 2025
). As filed with the Securities and Exchange Commission on March 6, 2025. Registration No. 333-. UNITED STATES ... Washington, D.C ... IGM BIOSCIENCES, INC ... IGM Biosciences, Inc ... IGM Biosciences, Inc ... ☐ ... IGM Biosciences, Inc ... IGM BIOSCIENCES, INC ... IGM Biosciences Inc.
Edit

Annual Report for Fiscal Year Ending 12-31, 2024 (Form 10-K) (IGM Biosciences Inc)

Public Technologies 06 Mar 2025
... imvotamab in oncology, IGM-7354, and IGM-2644 in oncology, partially offset by the advancement of Phase 1 clinical trials for imvotamab in autoimmune diseases prior to the 2025 Restructuring.
  • 1
×